Innocoll Inc.

Research, development and marketing of collagen-based products

Innocoll Inc. is a pharmaceutical company focusing on the development, research, manufacturing and marketing of collagen-based products.

Innocoll Technologies concentrates on the investigation and development of modified collagen-based products. Innocoll’s manufacturing facilities, Syntacoll GmbH and Syntacoll Pty, are located in Germany and South Africa.

Michael Myers, Ph.D., President and CEO
Denise Carter, Corporate VP and President, Innocoll Pharmaceuticals
Joan FitzPatrick, Corporate VP and VP R&D, Innocoll Technologies
David Prior, Ph.D., VP Business Development, Innocoll Technologies

Rolf Schmidt, Chairman and Director
F.William Schmidt, Director
Paul G. Oxholm, Director
Michael Myers, Ph.D.

42662 Kitchen Prim Court
Ashburn, VA 20148
USA

Innocoll focuses on the research and development of collagen-based products with a variety of pharmaceutical application areas. Their products are based on their CollaRX™ technology with its leading product Collatamp® G and LiquiColl®. These technologies target post-surgical infections, the therapy of infected or at-risk skin ulcers, reducing pain and oncology. While Collatemp® G is used for treating and preventing hard- and soft-tissue infections after surgical operations as a sponge or membrane, Liquicoll™ is a carrier of bioactive substances available in a liquid consistency for injections or semi-liquid material for the treatment of diverse tissue defects.